NIH Funding Cuts Disrupt Thousands of Clinical Trials, Putting Cancer and Infectious Disease Research at Risk.
A new study has found that nearly one in 30 clinical trials, including cancer research and infectious disease studies, have been disrupted by funding cuts to the National Institutes of Health (NIH). The disruptions affected more than 74,000 patients and put a significant amount of scientific evidence at risk. According to Dr. Anupam B. Jena, a study author and professor at Harvard Medical School, the interruptions were "surprisingly high" and included some of the most rigorous types of research.
The study, published in JAMA Internal Medicine, analyzed clinical trials that received NIH funding between February 2025 and August 15, 2025, and found that 383 trials were disrupted due to funding cuts. While more than 36% of the interrupted trials had been completed, another 35% were still recruiting patients, putting a strain on those involved in the research.
The interruptions disproportionately affected trials conducted outside the United States, with the Northeast region having the highest rate of disruptions. Cancer research and infectious disease studies were among the most affected areas, with over 115 trials and 97 trials disrupted, respectively.
Dr. CΓ©line Gounder, a medical contributor to CBS News, warned that the interruptions could lead to "avoidable waste" and put patients at risk. She noted that clinical trials are not light switches and that cutting off funding mid-trial can have significant consequences.
The NIH has responded to the criticism, stating that it is undergoing a strategic realignment to prioritize high-impact, high-urgency science. However, critics argue that the agency's decision-making process is being politicized, with some research prioritizing ideological agendas over scientific rigor and meaningful outcomes.
The impact of funding cuts on clinical trials has been a concern for years, but this latest development highlights the importance of continued support for biomedical research. As Dr. Francis Collins, former NIH director, noted, "every dollar that NIH gave out in 2024 is estimated to have returned $2.46 just in a year." The consequences of cutting off funding mid-trial can be severe, putting patients' lives at risk and undermining the scientific progress that our society relies on.
A new study has found that nearly one in 30 clinical trials, including cancer research and infectious disease studies, have been disrupted by funding cuts to the National Institutes of Health (NIH). The disruptions affected more than 74,000 patients and put a significant amount of scientific evidence at risk. According to Dr. Anupam B. Jena, a study author and professor at Harvard Medical School, the interruptions were "surprisingly high" and included some of the most rigorous types of research.
The study, published in JAMA Internal Medicine, analyzed clinical trials that received NIH funding between February 2025 and August 15, 2025, and found that 383 trials were disrupted due to funding cuts. While more than 36% of the interrupted trials had been completed, another 35% were still recruiting patients, putting a strain on those involved in the research.
The interruptions disproportionately affected trials conducted outside the United States, with the Northeast region having the highest rate of disruptions. Cancer research and infectious disease studies were among the most affected areas, with over 115 trials and 97 trials disrupted, respectively.
Dr. CΓ©line Gounder, a medical contributor to CBS News, warned that the interruptions could lead to "avoidable waste" and put patients at risk. She noted that clinical trials are not light switches and that cutting off funding mid-trial can have significant consequences.
The NIH has responded to the criticism, stating that it is undergoing a strategic realignment to prioritize high-impact, high-urgency science. However, critics argue that the agency's decision-making process is being politicized, with some research prioritizing ideological agendas over scientific rigor and meaningful outcomes.
The impact of funding cuts on clinical trials has been a concern for years, but this latest development highlights the importance of continued support for biomedical research. As Dr. Francis Collins, former NIH director, noted, "every dollar that NIH gave out in 2024 is estimated to have returned $2.46 just in a year." The consequences of cutting off funding mid-trial can be severe, putting patients' lives at risk and undermining the scientific progress that our society relies on.